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Abstract
Achieving a malaria-free world presents exciting scientific challenges as well as overwhelm-
ing health, equity, and economic benefits. WHO and countries are setting ambitious goals
for reducing the burden and eliminating malaria through the “Global Technical Strategy” and
21 countries are aiming to eliminate malaria by 2020. The commitment to achieve these tar-
gets should be celebrated. However, the need for innovation to achieve these goals, sustain
elimination, and free the world of malaria is greater than ever. Over 180 experts across
multiple disciplines are engaged in the Malaria Eradication Research Agenda (malERA)
Refresh process to address problems that need to be solved. The result is a research and
development agenda to accelerate malaria elimination and, in the longer term, transform the
malaria community’s ability to eradicate it globally.
Summary points
• The first malERA consultative process in 2011 identified a number of targets for invest-
ment and the scientific community has made progress across the research and
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development (R&D) continuum. Progress includes positive scientific opinion for a
malaria vaccine, advanced development of 3 nonpyrethroid insecticides, new genetic
technologies with the potential to alter malaria parasite transmission by the mosquito,
identification of markers of drug resistance, and development of Plasmodium vivax liver
stage assays as well as new collaborative approaches to mathematical modelling and
screening for active ingredients for drugs and insecticides.
• Scientific progress, however, has been matched with significant challenges. The expan-
sion of both insecticide and drug resistance threatens progress in affected countries.
Gaps in the knowledge base persist, from epidemiological and entomological tools to
guide programmes, particularly at low transmission levels, understanding the role of
low-density infections in maintaining transmission and developing appropriate diag-
nostics for programmes, biomarkers, and tools to detect and clear hypnozoites, to tools
to tackle residual transmission, receptivity, and prevention of reintroduction.
• In some areas, progress has been too slow, particularly in the creation of a tool kit to
tackle P. vivax malaria, investments in the development of new vector control tools,
almost all aspects of entomology, and in systematically testing solutions in the context
of the respective health and social systems.
• Malaria parasites and their infections continually evolve, creating new research and pro-
gramme challenges. In one region, human infections with P. knowlesi are rising, para-
sites with hrp2/3 deletions are evading detection by current rapid diagnostic tests
(RDTs), and current effective vector control tools are selecting for mosquitoes with both
physiologic resistance and behavioural traits like outdoor biting and resting.
• The malERA Refresh agenda proposes a broad agenda for transdisciplinary solutions to
the problems faced. It points to 3 areas in which innovation is critical: (i) iterative
improvements in drugs and vector control; (ii) transformative improvements in tools
and strategies to reduce, if not halt, the parasite’s capacity to transmit; and (iii) inte-
grated approaches in which a robust elimination strategy responds to local variations in
transmission dynamics, is tailored to the health and social system context, and draws
strength from other sectors.
Introduction
The 2011 malaria Eradication Research Agenda (malERA) was the first comprehensive analy-
sis of the science needed to support national elimination of malaria and the long-term goal of
its global eradication [1]. The 2011 malERA consultative process engaged a multidisciplinary
group, involving members of the infectious disease and malaria research and implementation
communities, and identified both emerging challenges and approaches to solving them. Five
years later, the review of progress and emerging challenges, as well as a more nuanced under-
standing of the implementation problems that need to be solved, drove the 2016 ‘malERA
Refresh’, with the intent to assess progress and the emergence of new challenges, examine cur-
rent hypotheses, and point to the key research and development areas that can advance the fea-
sibility of malaria elimination in the most challenging areas of the world.
Global goals for a reduction in malaria burden and elimination were published in 2 comple-
mentary documents in 2015: the Global Technical Strategy for Malaria 2016–2030 (GTS) and
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Action and Investment to defeat Malaria 2016–2030 (AIM), a global investment case for
financing and coordinating these efforts [2,3]. Other groups have expressed a vision of global
malaria eradication and underscored the need for R&D investments and country financing
[4]. Building on the goals expressed in the GTS and AIM, the World Health Organization
(WHO) has established a Strategic Advisory Group (SAG) to analyse future scenarios for
malaria, including eradication. WHO SAG has affirmed WHO’s long-standing commitment
to the goal of eradication, although it does not specify an end date for that goal [5,6].
There is not an assumption that 1 single ‘silver bullet’ will solve all of the challenges, but—
as was stated by Tachi Yamada in 2007—’imperfect tools applied imperfectly can still achieve
remarkable impact’, and a toolbox of solutions is needed that countries can draw upon and
adapt to their health and social systems context [7,8]. A strong research base is a keystone for
long-term progress in achieving the goals of the GTS. It is in this context that the malERA
Refresh Panels propose a multidisciplinary research agenda for researchers, programme imple-
menters, and research funders to accelerate problem solving and impact.
Accelerating to elimination
Elimination of malaria means the ‘interruption of local transmission (reduction to zero inci-
dence of indigenous cases) of a specified malaria parasite in a defined geographical area as a
result of deliberate activities. Continued measures to prevent re-establishment of transmission
are required’ (see Glossary, Table 1). A number of countries have been able or are on their way
to eliminating malaria by applying a combination of vector control, efficient case manage-
ment, and active surveillance strategies, all with existing tools for prevention, diagnosis, and
treatment. Between 2000 and 2015, 17 countries eliminated malaria [9]. A further 21 countries
have been identified as having the potential to eliminate malaria by 2020, comprising the “E-
2020” (Fig 1) [10,11]. There are key elements to the elimination strategy, reflected in high
uptake of core interventions by programmes and communities: a robust surveillance, report-
ing, and response system; prevention with a variety of ways to deliver insecticides and barrier
methods to stop infectious bites; and diagnosis and treatment with effective combination med-
ications. For this reason, WHO now frames national elimination as a continuum rather than
the achievement of milestones for specific phases [6]. The heterogeneous nature of malaria
across geographies means that a single approach will not work in all settings with the same effi-
ciency. According to the ‘Acceleration Hypothesis’, countries with high vectorial capacity, par-
ticularly in sub-Saharan Africa, may require measures to rapidly deplete the parasite
population [6,12], after which, locally tailored vector control, case management, and surveil-
lance strategies with active methods to investigate and clear infections can then more effec-
tively reduce transmission [12]. Whilst currently being considered and tested, strategies to
accelerate elimination (such as mass drug administration [MDA] with antimalarials, low dose
primaquine, complementary tools to address residual transmission, etc.) have not yet, and
may not be, proven to be widely effective in moving settings with high residual transmission
towards sustainable elimination. Ongoing research testing these tools and strategies is curated
in the open MESA Track database [13]. Across the malaria endemic world, there exist chal-
lenges, and it is here that innovation is required to achieve elimination and quicken its course.
Those challenges include areas of high receptivity (where the ecosystems are favourable for
malaria transmission), highly competent vectors, residual transmission, resistance to drugs
and/or insecticides, and areas where there are human populations that are not adequately
served by the health system.
Some key points emerge from experiences in elimination countries and are worth clarify-
ing, because they frame the context for evaluation of new tools to accelerate progress. First,
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Table 1. Glossary of terms. The meaning of the terms used in the malERA Refresh series are described here. The sources of the definitions are referenced;
where no reference is cited, the authors of this paper provided the definition.
Term Definition Reference
Asymptomatic parasitaemia The presence of asexual parasites in the blood without symptoms of illness. [14]
CHMI, also called human blood-stage
challenge model
An established malaria infection model in which a group of healthy volunteers are inoculated with
Plasmodium sporozoites via the bite of laboratory-reared infected female Anopheline mosquitoes or
via needle and syringe, followed by complete medical cure. Volunteers are closely monitored for
safety and clinical trial end points. CHMI allows the assessment of malaria vaccines, drugs,
diagnostics, and the study of immunological mechanisms.
[15–17]
CRISPR Gene-editing technology allowing for highly specific DNA modification. The technique is based on a
bacterially derived endonuclease, such as Cas9, which can cut DNA in any desired location given a
synthetic RNA guide sequence, the CRISPR. A new DNA sequence can then be introduced in that
position by DNA repair machinery.
Dormancy Any state of suppressed development (developmental arrest) that is adaptive (that is, ecologically or
evolutionarily meaningful and not just artificially induced) and usually accompanied by metabolic
suppression (can apply to the parasite or vector).
[18]
Efficacy A measure of the beneficial effect of an intervention in a controlled setting, for example, a
randomised controlled trial.
Effectiveness A measure of to what extent the efficacy of an intervention can be retained at the individual (clinical)
or the community (systems) level.
[19]
Elimination (of malaria) Interruption of local transmission (reduction to zero incidence of indigenous cases) of a specified
malaria parasite in a defined geographical area as a result of deliberate activities. Continued
measures to prevent reestablishment of transmission are required. Note that the certification of
malaria elimination in a country will require that local transmission is interrupted for all human
malaria parasites.
[14]
Eradication (of malaria) Permanent reduction to zero of the worldwide incidence of infection caused by human malaria
parasites as a result of deliberate activities. Interventions are no longer required once eradication
has been achieved.
[14]
Operational research Any research producing practically usable knowledge (evidence, findings, information, etc.) that can
improve programme implementation regardless of the type of research (design, methodology,
approach).
[20]
Persistence The continued presence of malaria parasites (in humans or mosquitoes) for an extended period,
generally after initial intervention has concluded.
Receptivity Receptivity of an ecosystem to transmission of malaria. Note that a receptive ecosystem should
have, e.g., the presence of competent vectors, a suitable climate, and a susceptible population.
[14]
Recrudescence Recurrence of asexual parasitaemia of the same genotype(s) that caused the original illness, due to
incomplete clearance of asexual parasites after antimalarial treatment. Note that recrudescence is
different than reinfection with a parasite of the same or different genotype(s) and relapse in P. vivax
and P. ovale infections.
[14]
Reinfection A new infection that follows a primary infection; it can be distinguished from recrudescence by the
parasite genotype, which is often (but not always) different than the genotype that caused the initial
infection.
[14]
Relapse Recurrence of asexual parasitaemia in P. vivax or P. ovale infections arising from hypnozoites. Note
that relapse occurs when the blood-stage infection has been eliminated but hypnozoites persist in
the liver and mature to form hepatic schizonts. After an interval, generally from 3 weeks to 1 year,
the hepatic schizonts rupture and liberate merozoites into the bloodstream.
[14]
Residual transmission Persistence of transmission after good coverage has been achieved with high-quality vector control
interventions, to which local vectors are fully susceptible. Note that both human and vector
behaviour is responsible for such residual transmission, such as people staying outdoors at night or
local mosquito vector species displaying behaviour that allows them to avoid core interventions.
[14]
SERCaP A description of an ideal antimalarial drug therapy, which, in a single-patient encounter, both
eliminates all parasites in the patient and provides individual protection from reinfection for at least 1
month after treatment.
[21]
Malaria stratification Classification of geographical areas or localities according to epidemiological, ecological, social, and
economic determinants for the purpose of guiding malaria interventions.
[14]
(Continued )
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elimination has been progressing using current tools and strategies; second, transmission
intensity varies widely between and within countries with different mosquitoes and parasite
species as well as different health systems and a myriad of varying challenges to the scale-up of
interventions; in addition, programmatic goals evolve as transmission changes (Fig 2). The
reduction of transmission may progress in a highly variable fashion, affected by ecologic (e.g.,
climate and outbreaks), biologic (e.g., vector or parasite resistance), and operational (e.g.,
health delivery system, sociopolitical and -economic status) challenges. Moreover, while some
countries have shown durable elimination [23], other countries have come close to but not
achieved elimination and then experienced resurgences [24]. New approaches are needed to
address vulnerability and receptivity so that elimination can be achieved and sustained in spite
of predictable risk of importations.
malERA Refresh process
The malERA Refresh was undertaken against the background of WHO GTS that was unani-
mously adopted by the World Health Assembly in 2015 as well as the Roll Back Malaria
(RBM) AIM framework [2,3]. Although focussed on malaria, the malERA process itself can be
a useful model for defining the research needs, strategies, and portfolios to eliminate and eradi-
cate neglected tropical diseases (NTDs).
The malERA Refresh process was overseen by a leadership group composed of Regina Rabi-
novich (chair, ISGlobal Barcelona Institute for Global Health and Harvard T.H. Chan School
of Public Health), Pedro Alonso (WHO Global Malaria Programme), Marcel Tanner (Swiss
TPH), and Dyann Wirth (Harvard T.H. Chan School of Public Health), and each consultative
panel was led by a chair and 1 or 2 cochairs [25]. The process was managed by the MESA Sec-
retariat (ISGlobal Barcelona Institute for Global Health). Diverse expert panels of scientists,
Table 1. (Continued)
Term Definition Reference
Subpatent infection Low-density blood-stage malaria infection that is not detected by standard diagnostic tools.
Submicroscopic infection Low-density blood-stage malaria infection that is not detected by conventional microscopy. [14]
Surveillance Continuous, systematic collection, analysis, and interpretation of disease-specific data and use in
planning, implementing, and evaluating public health practice. Note that surveillance can be done at
different levels of the healthcare system (e.g., health facilities, the community) with different
detection systems (e.g., case-based: active or passive) and sampling strategies (e.g., sentinel sites,
surveys).
[14]
Vector competence For malaria, the ability of the mosquito to support completion of malaria parasite development after
zygote formation and oocyst formation and development and release of sporozoites that migrate to
salivary glands, allowing transmission of viable sporozoites when the infective female mosquito
feeds again. Note that human malarias are transmitted exclusively by competent species of
Anopheles mosquitoes; various plasmodia are transmitted by competent species of mosquitoes of
the genera Aedes, Anopheles, and Culex and other haematophagous Diptera.
[14]
VIMT Vaccines that target the sexual- and mosquito-stage antigens, pre-erythrocytic vaccines that reduce
asexual- and sexual-stage parasite prevalence rates, asexual erythrocytic-stage vaccines that
inhibit multiplication of asexual stage parasites, or vaccines that target vector antigens to disrupt
parasitic development in the mosquito.
[22]
Vulnerability The frequency of influx of infected individuals or groups and/or infective anopheline mosquitoes.
Note that vulnerability is also referred to as ‘importation risk’. The term can also be applied to the
introduction of drug resistance in a specific area.
[14]
Abbreviations: CHMI, controlled human malaria infection; CRISPR, clustered regularly interspaced short palindromic repeats; malERA, Malaria
Eradication Research Agenda; SERCaP, Single-Encounter Radical Cure and Prophylaxis; VIMT, vaccines that interrupt malaria parasite transmission.
https://doi.org/10.1371/journal.pmed.1002456.t001
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programme managers, and decision makers were convened for 6 thematic areas. The themes
of the panels were adapted from the original malERA, reflecting the evolution of the knowl-
edge base even since the first malERA process in 2011. One panel examined tools for elimina-
tion (vector control, vaccines, diagnostics, and drugs), one panel tackled the application of
mathematical modelling to the challenges of combining interventions, and the health systems
panel also addressed policy research. New panels were created, one to look at the infectious
reservoir and one focussed on resistance to antimalarial drugs and insecticides (for the full list
of panels, see Table 2). A systematic literature search was performed for each theme to identify
papers published between 2010 and 2016. These papers were supplemented with suggestions
from panelists and projects in the MESA Track database of active projects. Each panel had 1
in-person meeting to assess the progress since malERA 2011 and discussed whether there had
been adequate efforts to address each area. Taking into consideration the major advances that
have taken place since the first malERA consultations, the panels highlighted specific chal-
lenges and indicated key opportunities to generate knowledge, tools, and strategies for malaria
Fig 1. Map of 21 countries with the potential to eliminate malaria by 2020. There are 91 countries and territories with ongoing malaria
transmission [9]. An analysis by WHO has identified 21 countries with the potential to eliminate by 2020: Algeria, Belize, Bhutan, Botswana, Cabo
Verde, China, Comoros, Costa Rica, Ecuador, El Salvador, Iran (Islamic Republic of), Malaysia, Mexico, Nepal, Paraguay, Republic of Korea,
Saudi Arabia, South Africa, Suriname, Swaziland, and Timor-Leste [10]. Countries and territories that have been certified malaria-free since 2007
are the United Arab Emirates (2007), Morocco (2010), Turkmenistan (2010), Armenia (2011), Maldives (2015), Sri Lanka (2016), and Kyrgyzstan
(2016) [9,10]. Argentina and Paraguay have formally requested certification of malaria elimination and are in the process. Note that not all countries
that have achieved zero indigenous cases for 3 consecutive years have sought certification from WHO. Map base vector created by Freepik.
https://doi.org/10.1371/journal.pmed.1002456.g001
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elimination (Box 1). Cross-links between the panels were ensured by cross-panel participation
and an online consultation of main findings (Fig 3).
A final meeting of all panel leaders reviewed results of this process and identified cross-cut-
ting themes that arose across several panels. These are described further in this paper: surveil-
lance, implementation science, and transmission and persistence. In addition, 2 areas—
entomology and P. vivax malaria—were recognised as research areas that were consistently
failing to garner adequate resources and thus scientific engagement. Rather than define spe-
cific areas for prioritisation, this research agenda lays out the rationale, context, and relevance
for a range of interlinked areas.
Cross-cutting priority research areas
Surveillance and towards surveillance–response approaches. Malaria programmes
continuously need data to direct their actions and resources, to gauge their impact, and,
Fig 2. Research accelerates progress towards malaria elimination goals. Research and development responds to the diverse and
evolving needs of malaria programmes to underpin elimination and eradication. ‘Scientific underpinning’: research agenda is
multidisciplinary and includes all human Plasmodium species. Quality evidence informs policies and decision makers. ‘Accelerated
path’: technical and operational innovations accelerate progress towards malaria elimination. ‘Enabling environment’: working
partnerships between malaria programmes and research institutions. The malaria community and the research community respond
effectively to opportunities afforded by other sectors, e.g., urbanisation, education. The malaria community and the research community
respond effectively to threats, e.g., natural disasters, conflict, stimulation of career progression and scientific leadership from malaria
endemic countries, and commitment to national malaria elimination goals by Ministries of Health, Finance, Science, Education, and
Tourism.
https://doi.org/10.1371/journal.pmed.1002456.g002
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particularly in the elimination context, to reorient their tools and strategies to clear infections
and stop transmission. The recent Ebola and Zika emergencies have highlighted the critical
role of strong health systems with diligent surveillance to enable rapid responses. Surveillance
is considered so fundamental to the malaria programme across the transmission spectrum that
it represents 1 of the 3 pillars of the GTS [2]. Surveillance itself is an intervention and must be
adapted to the respective epidemiological, health, and social system settings [12,26]. Informa-
tion gleaned from surveillance also informs the rational incorporation of new interventions. In
the context of elimination, however, surveillance must be both systematic and sufficiently
robust to capture the diminishing number of cases of disease. As elimination nears, surveil-
lance systems must be capable of correctly assessing the infection burden and direct actions;
for example, if surveillance data show very few cases, then the programme action can pivot to a
reactive approach to treatment around the index patient. Post elimination, surveillance sys-
tems must be capable of identifying cases that are reintroduced to prevent resumption of local
transmission.
Surveillance platforms like the District Health Information Software 2 (DHIS 2) are being
used to collect facility and community data across diseases. When fully functional, such plat-
forms collect dynamic quality-assured information that can be analysed to track temporal and
spatial changes in transmission [26,27]. High-quality information systems that collect real-
time data from incoming cases can spot early warning signals of drug resistance, reintroduc-
tion, and resurgence. High-resolution platforms based on geographic information systems
have been developed that collect, integrate, and share relevant data with various audiences
[27]. These surveillance–response systems are particularly useful for the detection of and
response to unevenly distributed transmission foci with sufficient detail as to depict the single-
household or hamlet level and are key to targeting the operational response. In addition to col-
lecting information on malaria infections, a quality malaria surveillance system should assess
drug efficacy against the parasites and assess mosquito vector populations and insecticide
Table 2. Using the themes from the first malERA process as a starting point, malERA Refresh was
organised by research themes that are relevant for malaria elimination and eradication and reflect cur-
rent hypotheses and new thinking.
malERA 2011 malERA Refresh 2017
• Introductory paper
• Basic science and enabling
technologies
• Drugs
• Vaccines
• Vector control
• Diagnosis and diagnostics
• Monitoring, evaluation, and
surveillance
• Modelling
• Cross-cutting issues for
eradication
• Lessons for the future
• Role of research in viral
disease eradication
• Overview and synthesis paper
• Basic science and enabling technologies
• Basic science and enabling technologies remained a key theme.
• Insecticide and drug resistance
• Given the evolving threat and search for solutions to resistance, a
panel was created to address resistance to insecticides and antimalaria
drugs in the malaria elimination context.
• Characterising the reservoir and measuring transmission
• To reflect the evolving and nuanced questions around
transmission, 1 panel examined the complexity of the parasite reservoir
and the challenges of measuring transmission.
• Diagnostics, drugs, vaccines, and vector control
• A synthetic assessment of product development for malaria was
included.
• Combination interventions and modelling
• A panel was created to tackle the power of combining tools and
predicting and increasing their impact using mathematical modelling.
• Health systems and policy research
• A panel was dedicated to the operational challenges of malaria
elimination in the context of existing health and social systems.
Abbreviation: malERA, Malaria Eradication Research Agenda.
https://doi.org/10.1371/journal.pmed.1002456.t002
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Box 1. Examples of challenges and opportunities to generate
knowledge, tools, and strategies for malaria elimination
See the papers in this series for the full description of where science has and has not
made progress since malERA and the considerations of the main challenges and exciting
opportunities going forward.
Biology
• There are significant gaps in the knowledge base and ability to tackle the non-falcipa-
rum Plasmodium species (P. vivax, P. ovale, P. malariae, P. knowlesi).
• Applying new technologies including CRISPR-Cas9 mediated gene drives, high-
throughput screening, metabolomics, and proteomics will help advance malaria
biology.
Tools and deployment strategies
• Strategies to stop the expanding resistance to pyrethroids, artemisinins, and partner
drugs are urgently needed.
• Tools to detect hypnozoites and P. vivax vaccine candidates remain to be developed.
• Deploying insecticides with novel modes of action.
• Two areas of promise for drug development are applying the controlled human
malaria infection (CHMI) models as a bridge to field efficacy of transmission-blocking
activity and high-throughput phenotypic screening for the ‘neglected’ product profiles,
including hypnozoites and gametocytes.
• Novel approaches to vector control tools are beginning to be explored, including using
drugs for vector control.
• Opportunities are emerging regarding monoclonal antibodies for passive immunity.
Understanding transmission and tackling residual transmission
• Major questions in understanding transmission remain, from gametocyte biology to
characterising and detecting the infectious reservoir.
• Advances are needed in entomological sampling, analysis, and entomological surveil-
lance systems.
• Innovation in genomics, serology, and geospatial tools can help sampling, validating
the absence of malaria transmission, and measuring receptivity.
Malaria programmes and systems
• Questions remain around the best composition, phasing, and threshold triggers for
intervention packages in different settings and as programmes advance along the elim-
ination continuum.
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resistance phenotypes [27,28]. The metrics to best provide this information are still under
evaluation.
Research is needed on 2 levels: to better understand low and zero transmission and to
develop measures that can be used by programmes. As countries approach elimination, vali-
dated epidemiological and entomological markers and efficient sampling strategies will be
required to detect transmission at low levels and to confirm the absence of transmission—i.e.,
the challenge of “measuring zero”. Molecular and serological approaches are being evaluated.
For example, identifying and responding to transmission foci would benefit from rapid and
noninvasive diagnostic tools that can be applied in nonclinical settings [27]. The balance
between predictive value and clinical or public health utility of diagnostic testing will differ in
different epidemiologic settings, e.g., as incidence declines, more test-positive cases will be
false positives. There are open questions regarding the programmatic impact of new tools to
identify subpatent infections that might sustain malaria parasite transmission in some settings
[27,29]. The critical balance is that the data collected need to be informative for the pro-
gramme but also practical in terms of collection and interpretation. The concept of “minimal
essential data” describes the balance between a collectable dataset and an informative one,
such that programmes can respond to the data [26,28]. As a malaria programme progresses
towards elimination, the data requirements will be continually changing and what is deemed
“essential” data will also change. There is a need to build an evidence base for effective pro-
grammatic responses, e.g., analysis of the systems for data collection, analysis and response to
minimise effectiveness decay, developing a portfolio of effective programmatic responses to
surveillance data [26], and using modelling and operational research to test specific questions
that could facilitate programme performance [12].
Implementation science. In contrast to the apparent simplicity of programmes that
depend on a single intervention (e.g., vaccines), malaria programmes use a diverse set of tools
in an integrated approach to prevent, detect, and treat infections. While the key elements (sur-
veillance, diagnosis, treatment, and prevention) are constant, there are important nuances and
evolution for each element as transmission declines. As new tools become available, they need
to be integrated into the existing intervention package(s). A critical challenge in malaria elimi-
nation is finding the optimal combination of interventions to maximise impact and mitigate
the risk of resistance and to modify this package in a timely fashion to respond to the increas-
ingly focal and rapidly changing transmission environment. Interventions have to be intro-
duced, altered, replaced, or possibly withdrawn through adaptive strategies responding to
• An area of promise for malaria programmes is testing and validating essential, collect-
able, and actionable data for programmatic decision-making.
• Advances in molecular technologies will help surveillance of resistance to insecticides
and drugs.
• Strategies for deploying future tools in the field need to be tested and modelling can
guide testing.
• Opportunities using systems-thinking approaches to identify where in the health sys-
tem effectiveness of interventions is lost and can be recovered.
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Fig 3. malERA Refresh process. malERA, Malaria Eradication Research Agenda; MESA, Malaria Eradication Scientific Alliance.
https://doi.org/10.1371/journal.pmed.1002456.g003
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shifting transmission, emerging resistance, and response to unique community issues and
needs.
Achieving universal coverage of preventive and curative interventions ‘is one of the biggest
opportunities to have a major impact on global mortality and morbidity’ and is also on the
critical pathway to elimination [30]. The programmes currently testing MDA approaches are
providing evidence of the relevance of community engagement and the need for high uptake
of interventions. Health systems and community engagement are both recognised as critical
elements in achieving high coverage, but research to define the successful operational criteria
is still needed; social science methods have not been fully applied to overcome these challenges
[26].
The efficacy of individual interventions is determined through a rigorous set of well-pow-
ered comparative trials to answer very specific questions that quantify the potential for impact
under controlled circumstances. Under these ideal conditions of very high coverage and ade-
quate use, the efficacy of an intervention equals its effectiveness. Under real field conditions,
measurable ‘effectiveness decay’ results from the impact of key elements of the health system,
including challenges in financing, procurement, work force, supply chain, and adherence.
However, the drivers of effectiveness decay vary and depend on the setting, i.e., unique cultural
and/or health systems [26]. malERA 2011 underlined the need to establish a tool for analysing
effectiveness decay within a health system, akin to a diagnostic tool for the system itself. It
would allow the malaria programme to identify bottlenecks, test different approaches to
overcome them, and thus minimise effectiveness decay [31]. Unfortunately, so far, too little
investment and progress have been seen in this area and work to understand and mitigate
effectiveness decay remains a priority [26].
Transmission and persistence. In elimination settings, the malaria programme takes on
an added focus: understanding the nuances that contribute to continued transmission in sce-
narios of low parasitaemia and low incidence and to the parasite’s persistence in host and vec-
tor. malERA 2011 stressed the importance of the infection and the transmission reservoir and
catalysed a search for tools to identify and interrupt transmission [1,21,22,32,33]. Notably, the
concept of a drug combination Single Encounter Radical Cure and Prophylaxis (SERCaP) was
developed [21] (see Glossary in Table 1). Today, new chemical entities with a ‘single encoun-
ter, radical cure’ profile are undergoing early clinical development. The concept of SERCaP
was that it could eliminate all parasites from the human (including the long-lived hypnozoites)
in a single encounter suitable for mass administration (including administration to healthy
people and the consequent need of a very good safety profile) and prophylaxis for at least 1
month after treatment, to outlast the typical development period of plasmodia parasites in
anopheline mosquitoes. Today, new chemical entities with a ‘single encounter, radical cure’
profile are undergoing early clinical development [29]. malERA 2011 expanded the concept of
transmission-blocking vaccines to the broader array of VIMT targets (vaccines that interrupt
malaria parasite transmission), which can be achieved at several stages of the parasite life cycle,
not just the sexual or mosquito stages, as in classical transmission-blocking vaccines [22]. Sev-
eral VIMT candidates for P. falciparum are in the development pipeline. Although P. vivax is
now included in the Malaria Vaccine Technology Roadmap strategic goals, VIMTs for P. vivax
have not advanced [29].
Research to characterise the transmission reservoir has evolved to a focus on the role of
low-density infections undetected by microscopy or current RDT in transmission [27]. Under-
standing determinants of the risk of infectiousness, understanding at what level of parasitae-
mia these are important for sustained transmission, and devising metrics and tools to measure
and target transmission are proposed as key needs [26,27,29,34]. Recently, a highly sensitive
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002456 November 30, 2017 12 / 17
RDT has been launched and demonstration studies are being planned to test how and when to
use this new tool [35].
Measuring zero transmission is a requisite for programmes that seek to eliminate malaria
and for evaluating tools in the development pipeline that aim to interrupt or reduce transmis-
sion. Validated, measurable epidemiological and entomological indicators of transmission are
needed. The papers in this series discuss the research agenda and potential solutions [12,26–
29,34].
Transmission needs to be reliably measured both at the mosquito and human levels, but the
tools available today only provide proxies for true transmission. Currently, vector control tools
are not able to interrupt all malaria transmission, and ‘residual transmission’ can persist even
in areas with good vector control coverage (see Glossary in Table 1). Residual transmission is
now recognised as a target for investigation and intervention, but there is no consensus yet on
how to quantify this concept. Novel tools to interrupt residual transmission as a complement
to traditional vector control are under development and include toxic sugar-baited traps,
endectocides, and targeted larviciding [27,29].
Gametocyes are the transmissible form of the parasite from humans and present a biologi-
cal opportunity because they are relatively few in number compared to other parasite stages.
Drug candidates with gametocytocidal properties are early in the pipeline and will need to be
tested for their ability to arrest the transmission cycle, and the search for tractable vaccine tar-
gets that attack gametocytes in the human host needs to continue [29,34]. Knowledge of the
drivers controlling gametocyte production is poor, e.g., understanding what environmental
conditions might favour an increased production of gametocytes and facilitate transmission
[27]. Moreover, there is a need to better define the relationship between gametocyte densities
and transmission for both P. falciparum and P. vivax. Reliable biomarkers for both gameto-
cytes and hypnozoites would enable this.
The key determinants for persistence and recrudescence remain to be established. In highly
seasonal settings, it has been demonstrated that humans can act as the parasite reservoir by
carrying gametocytes at levels beneath detection of current diagnostics, but the role of the
mosquito as a reservoir during those months is still poorly understood [27,34].
Major neglected areas critical to elimination
Entomology. Despite the indisputable merit of vector control tools in the reductions of
malaria morbidity and mortality and increasing vector resistance against insecticides, invest-
ment in this area has lagged [36]. This scenario extends from basic research through product
development and training.
Currently, collecting entomological data is laborious and trained entomologists and staff
are scarce. Programmes such as TDR and the US President’s Malaria Initiative have recognised
the need for improving national capacities for entomological monitoring and support training
efforts in some countries [37,38]. The recently adopted ’Global Vector Control Response’
report marks a significant commitment of WHO and member states to strengthen vector con-
trol within a collaborative framework [39]. Recent global outbreaks of other vector-borne dis-
eases such as Zika and chikungunya highlight the need for countries to garner the necessary
support for strengthening capacity in entomology and vector control that is also relevant for
malaria. malERA Refresh panelists agreed that medical entomology must have a central role in
the global health curriculum and in the training curriculum for Ministry of Health staff.
The efficacy of available vector control tools is diminished by residual transmission and the
enormous behavioural plasticity and biological variability of malaria vectors and is threatened
by the capacity of the mosquito to develop resistance in the face of high pressure from
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interventions. The papers in this malERA Refresh series offer potential solutions to be devel-
oped and tested [27–29,34].
Novel entomological markers for transmission are needed because the traditional measure
—entomological inoculation rate (EIR)—is not a practical or easily reproducible metric in
lower-transmission settings [27]. The gap in data collection capacities needs to be addressed
by testing and validating what constitute minimal essential, collectable, and actionable data.
New technologies are needed to generate robust data on species distribution, temporal and
spatial biting patterns, and spread of insecticide resistance, which would be actionable data
from entomologic surveillance in the future [27,29].
Vivax malaria (and 3 other species). Five species of Plasmodium infect humans. P. falcip-
arum has been a global priority due to its role as a driver of mortality and severe disease. How-
ever, P. vivax is geographically the most widely distributed form of human malaria, causes 13.8
million cases every year, and is associated with both significant morbidity and a risk for mor-
tality [9]. The research agenda presented in the malERA Refresh series is relevant to P. falcipa-
rum and P. vivax; specific challenges posed by P. vivax are highlighted in the thematic papers
and here.
There are important differences in the biology of P. vivax, particularly its ability to remain
quiescent in the liver, different kinetics and appearance of infectious gametocytes, and signifi-
cant differences in its clinical presentation and risk of recurrence. Unique drugs, diagnostics,
and different targets for vaccine development and strategies are required beyond what is avail-
able today.
malERA 2011 acknowledged hypnozoites as a challenge to P. vivax elimination, and this
remains the case, with a lack of diagnostics to identify carriers and safe efficacious treatments
to clear them [1,29]. Proteomic and metabolomic techniques have been suggested as possible
research tools to detect hypnozoites; additional in vitro studies are needed to expand current
knowledge of their biology and metabolism [34].
Countries with P. falciparum and P. vivax malaria seek to eliminate the disease entirely
rather than a single species. Thus, tackling P. vivax was considered critical in malERA 2011
and, while the biological and epidemiological knowledge base has significantly improved,
there is still a relatively weak pipeline of drugs and vaccines [1,27,29,34].
Tafenoquine is in late-stage development. It is a candidate drug that results in radical cure of
all circulating parasites and P. vivax hypnozoites in a single treatment and confers prophylaxis
for several weeks posttreatment. Results from a Phase III clinical trial show that single-dose tafe-
noquine reduces risk of relapse in patients with P. vivax malaria [29,40]. When tafenoquine
becomes available, it will not remove the need to test for glucose-6-phosphate dehydrogenase
(G6PD) deficiency, which affects 350 million people at risk for malaria and remains a consider-
able obstacle to effective treatment [41]. Novel point-of-care diagnostic tests for G6PD defi-
ciency are currently in late-stage development [29]. In the future, newly developed humanised
mouse models could help predict the haemolytic potential of drugs in the pipeline [29,34].
P. knowlesi poses unique challenges among the 5 malaria species, owing to its zoonotic
transmission. WHO convened an Evidence Review Group (ERG) to review existing data on P.
knowlesi, including an upward trend in incidence documented in Malaysia, and identify
knowledge gaps. The ERG articulated the need for evidence to better understand the likelihood
of human to human transmission [11].
Looking forward
Innovation and problem solving tailored to the local setting are critical to the long-term suc-
cess of the global malaria programme. Three types of innovation need to be pursued: iterative,
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breakthrough, and integrated. malERA Refresh is replete with examples: drugs to overcome
resistance, gene drive as a transformative technology, and the acceleration hypothesis as a test-
able approach to elimination and its interaction with the health system in highly endemic
countries. To pursue the opportunities proposed here for accelerating elimination, a diverse
landscape of funders is needed to prioritise research objectives according to their strategic
plans and stakeholders’ needs. A diligent monitoring of the uptake of the research questions in
this agenda and the impact of the evolving evidence base will be essential to keep the malaria
community on course.
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